XCEEDANCE
3.3.2020 09:02:14 CET | Business Wire | Press release
Xceedance , a global provider of insurance consulting, managed services, technology, data sciences, and blockchain solutions, today launched its life insurance and reinsurance practice and announced the establishment of an office in Liechtenstein to serve life re/insurance markets.
The practice focuses on partnering with existing and start-up life re/insurance organisations and insurtech providers, offering services such as interim management, strategic consulting, product development, actuarial services, sales strategy consulting, Solvency II Pillar 1-2 support, and reinsurance optimisation. In addition, Xceedance can help carriers with legacy transformation to better manage new and existing business, and to transact run-off portfolios.
Markus Brugger and Mark Lucas will jointly direct the newest international office of Xceedance, as leaders of the life insurance and reinsurance sectors respectively.
“Liechtenstein is a significant financial services hub, including for worldwide life re/insurers, and our rapidly growing company is especially skilled in supporting the full range of insurance operations, as we help our global clients gain new business, grow revenues and minimise expenses,” said Arun Balakrishnan, CEO, Xceedance. “We are excited to locate an office in Liechtenstein and expand opportunities for direct interaction with diverse life re/insurance organisations, both in the EMEA region and worldwide.”
“Liechtenstein is a well-established global insurance marketplace, and Xceedance can help and support life re/insurers worldwide to strengthen their operations and enter new markets,” said Markus Brugger.
“We are excited to join a dynamic company such as Xceedance and look forward to building the company’s life re/insurance consulting and technology services to assist the industry in addressing pressing challenges and diverse market opportunities,” said Mark Lucas.
Mr. Brugger has 30 years of life re/insurance experience and was president of the Liechtenstein Insurance Association from 2012 to 2014. He has held senior roles with Winterthur Re, Cologne Re, and PartnerRe, and was CEO for 17 years at PrismaLife and Liechtenstein Life. Mr. Brugger joins Xceedance from Grant Thornton Liechtenstein/Switzerland, where he led the insurance advisory practice.
Mr. Lucas has 35 years of industry experience at Guy Carpenter in Denmark, U.S. Re in Switzerland, and most recently at JLT Re in Switzerland, where he was general manager. Mr. Lucas has developed several new reinsurance products over his career and brings a wealth of life reinsurance knowledge to Xceedance.
About Xceedance
Xceedance (www.xceedance.com ) is a global provider of strategic consulting, actuarial, and managed services, technology, and data sciences to property/casualty and life insurance organisations. Domiciled in Bermuda, with offices in the United States, United Kingdom, Germany, Liechtenstein, Poland, India, and Australia, Xceedance helps re/insurers launch new products, drive operations, implement intelligent technology and blockchain solutions, deploy advanced analytic capabilities, and achieve business process optimisation. The experienced insurance professionals at Xceedance enable re/insurers, brokers, TPAs, agents, and program administrators worldwide to enhance policyholder service, enter new markets, boost workflow productivity, and improve profitability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005108/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom